59 related articles for article (PubMed ID: 8700540)
1. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD.
Sonoda H; Nishida K; Yoshioka T; Ohtani M; Sugita K
Oncogene; 1996 Jul; 13(1):143-9. PubMed ID: 8700540
[TBL] [Abstract][Full Text] [Related]
2. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
3. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of tropomyosin-2 expression in c-Jun-transformed rat fibroblasts involves induction of a MEK1-dependent autocrine loop.
Ljungdahl S; Linder S; Franzén B; Binétruy B; Auer G; Shoshan MC
Cell Growth Differ; 1998 Jul; 9(7):565-73. PubMed ID: 9690624
[TBL] [Abstract][Full Text] [Related]
5. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
6. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
7. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
[TBL] [Abstract][Full Text] [Related]
8. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
Rapp UR; Troppmair J; Beck T; Birrer MJ
Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells.
Kieser A; Seitz T; Adler HS; Coffer P; Kremmer E; Crespo P; Gutkind JS; Henderson DW; Mushinski JF; Kolch W; Mischak H
Genes Dev; 1996 Jun; 10(12):1455-66. PubMed ID: 8666230
[TBL] [Abstract][Full Text] [Related]
10. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.
Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM
Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747
[TBL] [Abstract][Full Text] [Related]
11. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
Du J; Jiang B; Coffey RJ; Barnard J
Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
[TBL] [Abstract][Full Text] [Related]
12. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
13. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.
Barradas M; Monjas A; Diaz-Meco MT; Serrano M; Moscat J
EMBO J; 1999 Nov; 18(22):6362-9. PubMed ID: 10562548
[TBL] [Abstract][Full Text] [Related]
14. v-raf confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation.
Büscher D; Dello Sbarba P; Hipskind RA; Rapp UR; Stanley ER; Baccarini M
Oncogene; 1993 Dec; 8(12):3323-32. PubMed ID: 8247534
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
[TBL] [Abstract][Full Text] [Related]
16. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
Topol LZ; Marx M; Calothy G; Blair DG
Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of the p72-74 RAF-1 kinase in 3T3 fibroblasts expressing ras or src oncogenes.
Reed JC; Yum S; Cuddy MP; Turner BC; Rapp UR
Cell Growth Differ; 1991 May; 2(5):235-43. PubMed ID: 1888699
[TBL] [Abstract][Full Text] [Related]
18. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.
Su Z; Shi Y; Friedman R; Qiao L; McKinstry R; Hinman D; Dent P; Fisher PB
Nucleic Acids Res; 2001 Apr; 29(8):1661-71. PubMed ID: 11292838
[TBL] [Abstract][Full Text] [Related]
19. v-Jun represses c-jun proto-oncogene expression in vivo through a 12-O-tetradecanoylphorbol-13-acetate-responsive element in the proximal gene promoter.
Hussain S; Kilbey A; Gillespie DA
Cell Growth Differ; 1998 Aug; 9(8):677-86. PubMed ID: 9716184
[TBL] [Abstract][Full Text] [Related]
20. Distinct involvement of cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells.
Olivo C; Vanni C; Mancini P; Silengo L; Torrisi MR; Tarone G; Defilippi P; Eva A
Oncogene; 2000 Mar; 19(11):1428-36. PubMed ID: 10723134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
